Clinical Trial Update: Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2 [Phase 2]

View source ↗

Summary

Phase 2 study of irradiated donor lymphocyte infusion plus high-dose interleukin-2 for metastatic melanoma and renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• High-dose interleukin-2 (interleukin-2)
• Irradiated donor lymphocyte infusion (donor lymphocyte infusion)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Metastatic Malignant Melanoma and Renal Cell Carcinoma | Phase 2 | Status: TERMINATED